Eli Lilly Grants Compassionate Use of Retatrutide to 79-Year-Old Patient Amid Access Concerns

The request occurred outside ongoing phase 3 trials and triggered internal interest at health agencies, indicating the recipient held connections that facilitated expedited review. Retatrutide, which activates GLP-1, GIP, and glucagon receptors, produced mean weight reductions of 17.5% at 24 weeks in the 2023 NEJM phase 2 study of 338 adults with obesity, yet that trial excluded participants over age 75. Compassionate-use pathways require demonstration of serious or immediately life-threatening conditions and exhaustion of approved therapies; obesity alone rarely meets this bar without documented comorbidities such as heart failure or severe sleep apnea.

Equity questions arise because the same drug remains unavailable to thousands of patients meeting trial criteria while one individual bypassed standard allocation. Historical FDA data show compassionate-use approvals for obesity drugs have been limited to cases with life-threatening complications, yet no public criteria distinguish this request. Lilly has not disclosed how many similar applications were denied.

Phase 3 results expected in 2025-2026 will determine whether retatrutide receives broad approval; regulators will need explicit guidance on age and comorbidity thresholds to prevent ad-hoc exceptions from becoming precedent.